Mendaera, a robotics company, announced it has been granted FDA 510(k) clearance for Focalist, a handheld robotic system, which aims to combine handheld robotics with real-time imaging to enable clinicians to place needles with precision. Mendaera said the system integrates robotics, ultrasound imaging and advanced software to make medical procedures more accessible. Among Focalist's features are touchscreen targeting, robotic needle positioning and continuous needle depth tracking, enabling a

Restore Medical, a medtech company focusing on heart failure therapies, announced the closing of a $23 million Series B funding round. Pitango HealthTech co-led the round with the European Innovation Council (EIC) Fund, with participation from existing investors, including Peregrine Ventures. WHAT IT DOES Restore Medical treats heart failure with transcatheter therapies designed to restore hemodynamic balance and improve clinical outcomes. The company's flagship product, ContraBand, is a revers

KILLEEN, Texas, July 8, 2025 /PRNewswire/ -- Integrated Pain Associates ("IPA") (), a Triton Pacific Healthcare Partners ("Triton Pacific") portfolio company, is pleased to announce a partnership with Lubbock Spine Institute ("LSI"), a leading provider of interventional spine and pain management services across West Texas with 21 physicians and advanced practice providers. Headquartered in Killeen, TX and with locations across the state, IPA has significantly expanded its geographic reach since

Laser therapy offers burn patients relief from painful and restrictive scars — improving mobility, reducing pain and transforming recovery with real results. It’s changed my life. It’s helping me heal better, feel better and get to where I want to be.” — Tonya Lambert LUBBOCK, TX, UNITED STATES, July 8, 2025 / EINPresswire.com / -- When it comes to managing the painful and restrictive scars left behind after burn injuries, treatments have come a long way. What was once limited to at-home care an

PHOENIX, July 8, 2025 /PRNewswire/ -- Aqueous Health announced today that healthcare industry veteran, Robert (Bob) J Zollars has joined its Board of Directors. "We are very pleased to have Bob on our Board to help guide our strategy and plans," said Dan Eckert, Chairman & CEO of Aqueous. "I am personally excited to work with Bob directly again and to benefit from his guidance as we build Aqueous into a market leader." Zollars has led eleven companies as president or CEO, ranging in size from $1

New facility includes expanded footprint to better serve the community GREENWOOD, S.C., July 8, 2025 /PRNewswire/ -- Greenwood Rheumatology, a leading provider of comprehensive rheumatologic care, is proud to announce its move to a larger, state-of-the-art facility at 210 Overland Drive in Greenwood, effective July 8, 2025. The practice is expanding to meet the growing needs of the community. The new location will offer more exam rooms, enhanced patient amenities, and increased capacity to provi

DRUGAI抗体–抗原的结合亲和力是治疗性抗体开发的核心：药效依赖于高特异性的结合能力以及亲和力的可控性。研究人员在此提出了Graphinity，一种基于抗体–抗原结构构建的等变图神经网络架构，可实现实验结合亲和力变化（ΔΔG）预测的Pearson相关系数高达0.87。然而，正如以往方法所示，该模型在目前可用的少量实验数据上存在过拟合现象，且在训练–测试划分上表现出较差的稳健性。为了探究实现ΔΔG泛化预测所需的数据量与类型，研究人员构建了两个大规模合成数据集：近100万个由FoldX生成的ΔΔG样本，以及超过2万个由Rosetta Flex ddG生成的样本。结果表明，当前的实验数据量不足以支撑准确稳健的ΔΔG预测，或许还需数量级上的增长。此外，除了数据体量，数据的多样性也是影响模型预测性能的重要因素。本研究为未来预测方法的开发和数据采集工作提供了数据需求的下限估计，强调了推动“可泛化的亲和力预测”迈向现实所需的关键基础。抗体通过与靶抗原的特异性结合发挥其生理与治疗功能。因而，在治疗性抗体的开发过程中，控制其结合亲和力始终是筛选与优化候选分子的核心目标。除了亲和力本身，抗体的“可开发性

☝ 点击上方 一键预约 ☝   最新最热的医药健康新闻政策2025年，中国医药电商市场迎来结构性转折点。中康CMH数据显示，O2O医药配送市场规模同比增长35.2%，GMV突破1200亿元。而医药电商的另一大赛道，传统B2C平台增速明显放缓，京东健康2024年营收增速仅8.6%，拼多多医药B2C业务的增速也从过去的超高增速下滑至10%左右，但增速仍然保持在全行业第一。曾经主导线上药品交易的B2C模式，正面临前所未有的增长困境，但O2O赛道则市场空间广阔。2024年以来，线上医保支付逐步向O2O渠道开放，为用户打通“在线挂号+医保结算+配送到家”的全流程路径，倒逼传统电商平台转型，京东健康、阿里健康等头部玩家纷纷加码O2O模式。据医药行业资深人士刘小东（化名）透露，2024年全年，美团买药GMV已超过500亿元，而拼多多的医药品类GMV在700亿元左右。据财报数据，京东健康2024年全年总收入达到 582亿元，而阿里健康在2024年财年，公司总收入为306亿元。历经多年发展的医药电商行业，如今正到中场。一方面是头部电商平台不断放缓的增速，另一方面是抖音、小红书等兴趣电商的兴起，新的玩法和

点击上方的 行舟Drug ▲ 添加关注文章信息源于FDA，登载该文章目的为更广泛的传递行业信息，不代表赞同其观点或对其真实性负责。文章版权归原作者及原出处所有，文章内容仅供参考。本网拥有对此声明的最终解释权，若无意侵犯版权，请联系小编删除。学如逆水行舟，不进则退；心似平原走马，易放难收。行舟Drug每日更新 欢迎订阅+医药大数据|行业动态|政策解读

QUEENS, N.Y., July 8, 2025 /PRNewswire/ -- Biotia, a biotechnology company pioneering the development of novel infectious disease diagnostics, today announced its selection as an awardee in the Humans in Space (HIS) Challenge, a global innovation program led by South Korea–based Boryung Corporation. Biotia was selected as the first ever recipient for Orbital Launch Funding (OLF), a core HIS program that provides funding, strategy sessions, and partner connections to aid startups in successfully